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Acute Lymphoblastic Leukemia
MLL/GAS7 fusion in a pediatric case of
t(11;17)(q23;p13)-positive precursor B-cell
acute lymphoblastic leukemia
MLL/GAS7, resulting from t(11;17)(q23;p13), has
been reported in one case of treatment-related
acute myeloid leukemia (AML). We present a de
novo case of t(11;17)-positive pediatric acute lym-
phoblastic leukemia. Fluorescent in situ hybridiza-
tion and reverse transcriptase polymerase chain
reaction analyses revealed an MLL/GAS7 chimera
identical to the one previously described in AML.
The molecular genetic features of MLL/GAS7 and
the clinical impact of t(11;17) are discussed.
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To date, the 5’ part of MLL has been shown to fuse with
the 3’ part of approximately 50 different genes in acute
myeloid leukemia (AML), chronic myeloid leukemia,
myelodysplastic syndromes, acute lymphoblastic leukemia
(ALL), and lymphomas.1 Some of these fusions are quite
common, such as MLL/AFF1(AF4) [t(4;11)(q21;q23)] in ALL
and MLL/MLLT3(AF9) [t(9;11)(p21;q23)] in AML, whereas
many of them have only been reported in single cases, such
as the MLL/GAS7 [t(11;17)(q23;p13)] in therapy-related
AML.1,2 Although the prognostic impact of the frequent
MLL fusions is well known,3,4 the clinical ramifications of
the infrequent chimeras are unknown. Considering that
most treatment protocols are based on the presence of cer-
tain genetic changes in AML and ALL, it is important to
describe such rare MLL fusions, with the aim that other
groups will report additional cases, thus increasing the clin-
ical information available for the medical community, as
recently exemplified by the rare MLL/ARHGAP26(GRAF)
fusion, generated by a t(5;11)(q31;q23), in pediatric AML.5-7
For this reason, we present here the molecular genetic and
clinical features of the first t(11;17)(q23;p13)-positive ALL
shown to harbor the MLL/GAS7 chimera.
A previously healthy 15-month old girl was admitted to
hospital in April 2005 because of fever and abnormal blood
values (hemoglobin 62 g/L, platelet count 68×109/L, and
white blood cell count 3.9×109/L with 28% blasts). The
clinical examination revealed hepatomegaly; there was no
splenomegaly or mediastinal mass. The bone marrow was
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Figure 1. A. Partial karyogram showing the t(11;17)(q23;p13). The derivative chromosomes 11 and 17 and the chromosomal breakpoints are
indicated by arrows. B. Southern blot analysis of BamHI-, HindIII- and EcoRI-digested DNA from the t(11;17)-positive ALL (L) and from two
healthy individuals (N1 and N2) using the MLL probe B859. Aberrant fragments are indicated by asterisks. M is λ DNA/HindIII fragments. C.
FISH using RP11-770J1 for the MLL gene (green signal), CTB-104H12 and RP11-888L24 for the GAS7 gene (red signal), and wcp17 (blue sig-
nal). Fusion signals of MLL and GAS7 are seen on both the der(11) and the der(17) of the t(11;17). D. Amplification of a chimeric MLL/GAS7
transcript. Total RNA was reverse-transcribed, and cDNA was used as a template in PCR amplification using MLL-3735F (CCCATCAGCAAGAGAG-
GATCCTGC) and GAS7-700R (CATCGTGTCTGG GTGAGGGAACG) primers (Lane 1). Two microliters of the first PCR product were used in a second
PCR with MLL-3878F (AGTCAAGCAAGCAGGTCTCCCAGC) and GAS7-634R (CTGCTTTTTGCTTGGCGATGAGG) (Lane 2). M: 100 bp DNA ladder. E
and F. Partial sequence chromatogram showing that nt 4241 (NM_005933.2; exon 9) of MLL was fused in-frame with nt 345 (NM_201433.1;





hypercellular, containing mainly blasts. Flow cytometric
four-color analysis showed that 95% of the bone marrow
cells were positive for CD34, CD19, CD22, CD24, CD15,
CD123, TdT, and cCD79a but negative for CD10. A diagno-
sis of precursor B-cell ALL was made. Genetic analyses of a
diagnostic bone marrow sample revealed the karyotype
46,XX,t(11;17)(q23;p13)[25] and an MLL rearrangement
(Figure 1A and B). Further molecular studies were negative
for BCR/ABL1, ETV6/RUNX1, TCF3/PBX1, and FLT3 muta-
tions. A monoclonal IgH rearrangement was identified,
characterized and used for evaluating minimal residual dis-
ease by real-time polymerase chain reaction (PCR). Based
on the finding of an MLL rearrangement, the girl continued
treatment according to the intensive arm of the Nordic
NOPHO-ALL 2000 protocol. Complete cytogenetic, fluores-
cent in situ hybridization, morphologic, flow cytometric, and
PCR remission was achieved on day 29. At present, 14
months after diagnosis, she remains in remission. Southern
blot analysis, using the MLL probe B8596, yielded two extra
bands in the BamHI, HindIII, and EcoRI digestions (Figure
1B). The t(11;17)(q23;p13) was then further characterized
by FISH using wcp11, wcp17, the bacterial artificial chro-
mosome (BAC) RP11-770J1 (covering MLL), and BAC CTB-
104H12 and RP11-888L24 for the GAS7 locus. The FISH
analysis revealed fusion signals of MLL and GAS7 on both
derivative chromosomes 11 and 17 (Figure 1C). Five micro-
grams of total RNA were reverse-transcribed, PCR-ampli-
fied, and sequenced as described previously.6 The reverse
transcription (RT)-PCR with MLL-3735F and GAS7-700R,
nested PCR with MLL-3878F and GAS7-634R, and
sequence analyses of the two amplified cDNA fragments
revealed an in-frame fusion of exon 9 of MLL with exon 2
of GAS7 and, in the smaller fragment, of exon 10 of MLL
with exon 2 of GAS7 (Figure 1D-F), both identical to the
previously reported MLL/GAS7 transcripts in AML.2
As a consequence, the translocation places the GAS7
gene under the control of the MLL promoter. The putative
MLL/GAS fusion protein would retain the AT-hook DNA
binding domain, the DNA methyl transferase motif, and the
transcription repression domain of MLL and all the func-
tional domains of the GAS7 protein.2 MLL/GAS7 has been
shown to transform multipotent hematopoietic progenitors
and to induce mixed lineage leukemia in mice.8 The present
case shows that the MLL/GAS7 fusion may result in ALL as
well as in AML, akin to what has been reported for other
MLL chimeras.1
Only four acute leukemias with t(11;17)(q23;p13), two of
which with confirmed MLL/GAS7 chimeras, have been
reported to date (Table 1). Thus, it is difficult to draw any
firm conclusions as regards its clinical impact. However, all
patients have been children and pronounced leukocytosis
was reported in two of them. Furthermore, it may be note-
worthy that both patients with ALL, i.e., the present case
and one previously published,9 responded well to treatment.
On the other hand, the two patients with AML both suc-
cumbed to their disease within a few months. Thus, the
prognostic impact of MLL/GAS7 may differ between AML
and ALL.
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Table 1. Clinical, immunophenotypic, and genetic features of t(11;17)(q23;p13)-positive acute leukemias reported in the literature.
Reference Diagnosis Sex/age CNS WBC Immunophenotype Cytogenetics Molecular Survival
(×109/L) genetics (mo)
10 AL bi M/5 mo Yes 400 HLA-DR+, CD19+, CD33+, t(11;17) (Dx) NR <1
CD13+, TdT–, CD10–, CD20–,sIg–,CD14– t(11;17),+8 (Rel)
2 t-AML M4 M/14 yrs NR NR NR t(11;17) MLL/GAS7 4
9 ALL M/9 mo NR 900 pro-B t(11;17),+22 MLL R 59+
Present case ALL F/15 mo No 3.9 CD34+, CD19+, CD22+, CD24+, CD15+, CD123+, t(11;17) MLL/GAS7 14+
TdT+, cCD79+, CD10–
AL bi: acute biphenotypic leukemia (FAB type M1/L2); ALL: acute lymphoblastic leukemia; CNS: central nervous system involvement; Dx: diagnosis; F: female;
M: male; mo: months; NR: not reported; R: rearrangement; Rel: relapse; t-AML M4: treatment-related acute myeloid leukemia (FAB type M4) occurring after
chemotherapy (cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide), radiotherapy, and surgery for neuroblastoma; WBC: white blood cell count;
yrs: years; +: alive at the time of reporting.. 
